Join
Live feed
·
INSIDERFilingvia Quantisnow
Oramed Pharmaceuticals Inc. logo

President and CEO Kidron Nadav converted options into 109,000 shares, increasing direct ownership by 3% to 3,355,238 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ORMP· Oramed Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ORMP (Oramed Pharmaceuticals Inc.) and more on Quantisnow.